Syracuse AndroGel Testosterone Therapy (TRT) Lawsuit

AndroGel is a brand of testosterone replacement therapy (TRT) manufactured by Abbvie.  According to Abbvie's website, AndroGel is the "#1 prescribed topical testosterone replacement therapy" and is used to "treat adult males who have low or no testosterone." 

Available package inserts recommend a starting dose for AndroGel 1% at 50 mg (4 pump actuations, two 25 mg packets, or one 50 mg packet), applied topically once daily in the morning to the shoulders or upper arms and/or abdominal area.  In addition to starting dosages, historical AndroGel package inserts have warned patients about increased risks for, e.g., prostate cancer, increased hematocrit, spermatogenesis, hepatic impairment, edema, gynecomastia, sleep apnea, and hypercalcemia.  However, little if any information has been disclosed about a potential increase in risk for:

  • heart attack;
  • stroke;
  • blood clots; or
  • death.

Following the FDA Safety Alert released in January of 2014, Bottar Leone, PLLC began investigating AndroGel labeling, including whether patients were sufficiently aware of statistically significant risks associated with use of the medication.  If Abbvie knew or should have known of the risks and did not disclose all-together, or provided an inadequate warning to physicians and consumers on bottles and package inserts, it may be liable for damages, including compensation for:

  • pain and suffering;
  • lost wages;
  • medical bills; and
  • wrongful death.

To speak with a member of our legal team to learn more about whether your use of AndroGel, Androderm, Axiron, Androud 10, Depo-Testosterone, Bio-T-Gel, Delatestryl, Fortesta, Straint, Testin or Testopel caused a cardiac or embolic event, contact us at (800) 336-5297, or by email at info@bottarleone.com.